This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
The field of genomic medicine has reached a true turning point. In June 2022, the European Medicines Agency approved an adeno-associated viral (AAV) vector-based therapy for adults with Hemophilia A, making the treatment available to an estimated 3,200 eligible patients. [1] CEVEC became part of Cytiva in October 2022.
Pharmaceutical companies are accountable for ensuring that their medicine is safe when it comes into the hands of patients. Specific apps could also alert healthcare providers if vulnerable patients are failing to scan their medicine. This technology can also play an important role in supporting virtual clinical trials.
However, caveats surrounding the stochastic off-target outcomes of cleaving both strands of the DNA helix to elicit a gene modification remain a source of concern. Traditional CRISPR-Cas9 technology relies on generating a DSB in the DNA to facilitate a genetic modification. Base editing to get cell therapies on point.
Advancement in DNA sequencing technologies have resulted in noteworthy developments in various healthcare-related research fields, such as diagnostics and personalized medicine. Moreover, the manual protocols require extensive manipulation, costly reagents and long duration of skilled genomic library production.
The Challenge: The demands of many labs simultaneously beginning COVID-19 screening programs are leading to a scarcity of resources like pipette tips and reagents. Medicine in Oxford, Biogazelle, a biotechnology company in Ghent, and the Centre For Proteome Research at the University of Liverpool. delays where reagents are in.
Results show the protocol demonstrated a 30Gb+ yield of long DNA reads raw data of an E. The FMv8 protocol introduces a needle-aspirate-based, cell-resuspension step prior to cell lysis that boosts DNA recovery. Elsewhere around the globe: RevoluGen – U.K.-based
Prestige BioPharma – Singapore-based Prestige received a positive opinion from the European Medicines Agency Orphan Drug Commission (COMP) for its first-in-class anti-PAUF monoclonal antibody, PBP1510, for the treatment of pancreatic cancer. Talking Medicines – Scotland’s Talking Medicines will join Tech Nation’s Applied AI 2.0
Hereditary Angioedema (HAE), like so many other rare diseases, is highly complex, and patients, their families and caregivers often undergo years of strain trying to understand their disease, get a definitive diagnosis and gain access to the medicines they need. At Takeda we are a committed champion for the patients we serve. Interactions.
Prior to starting Fountain Therapeutics in 2018, with co-founders Tom Rando, MD, PhD and Tom Cheung, PhD, Dr. Rodgers was an assistant professor at The Eli and Edythe Broad Center for Regenerative Medicine and Stem Cell Research at the Keck School of Medicine of The University of Southern California (USC).
Accurate monitoring of Epstein-Barr virus DNA levels is critical, as they are associated with a range of life threatening-diseases including cancer in transplant patients. This is the first quantitative in vitro diagnostic test for Epstein-Barr virus (EBV) DNA in the United States.
to obtain comparable results when measuring levels of BKV DNA. The test offers an alternative to lab-developed tests (LDTs) or Analyte Specific Reagent (ASR) combinations, potentially minimising variability and complexity in testing, reducing workload and alleviating risk for laboratories. IU/mL and an expanded linear range from 21.5
We organize all of the trending information in your field so you don't have to. Join 21,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content